On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $96.57 which represents a decrease of $-1.33 or -1.36% from the prior close of $97.9. The stock opened at $96.05 and ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

The global hepatitis B diagnostic tests market is on the cusp of substantial expansion, driven by a combination of increasing disease incidence, heightened global awareness campaigns, and rapid ...

As a former trial attorney with more than a decade of litigation experience, Jamie L. Pfeiffer writes trustworthy, engaging ...

As the No.1 University in the world for sport-related subjects, we offer unrivalled research, teaching and partnerships across sport, exercise and health sciences. Our expertise spans the fields of ...

"The global regenerative medicine markets comprises of many key market players competing for markets shares like Novartis AG ...

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter ...

TD Cowen raised the firm’s price target on Gilead (GILD) to $95 from $85 and keeps a Buy rating on the shares. The firm updated its model ...

Trump’s newly named WH chief of staff Susie Wiles retained her position as co-chair of the lobbying firm Mercury Public ...

Some of Mercury’s other clients, highlighted on its website, include Gilead Sciences, Pfizer, Tesla, Uber, Kaiser Permanente, AT&T, NBC Universal, Gavi: The Vaccine Alliance, and the nation of Qatar. ...

Gilead Sciences, Inc. (NASDAQ:GILD ... The press release, slides and supplementary data are available on the Investors section of our website at gilead.com. The speakers on today's call will be our ...